# First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Source: https://onco.cc/trials/nct07332455/  
OnCo record `nct07332455` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GSK5471713 in prostate cancer, run by GlaxoSmithKline, now recruiting.

## Summary

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC is a phase 1/2 interventional study registered as NCT07332455 by GlaxoSmithKline, with 54 participants planned, started 2026-02-10 and due to reach its primary completion in 2028-03-24. Interventions recorded: GSK5471713.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07332455
- Phase: 1/2
- Setting: A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Sponsor: GlaxoSmithKline
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT07332455: https://clinicaltrials.gov/study/NCT07332455

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07332455.json